Sign Up Today and Learn More About GRIN Therapeutics Stock
Invest in or calculate the value of your shares in GRIN Therapeutics or other pre-IPO companies through EquityZen's platform.
GRIN Therapeutics Stock
GRIN Therapeutics is at the forefront of developing targeted therapies for rare, severe neurodevelopmental disorders.
About GRIN Therapeutics Stock
Founded
2021
Headquarters
New York, NY, US
Industries
Science and Engineering, Health Care, Biotechnology
GRIN Therapeutics Press Mentions
Stay in the know about the latest news on GRIN Therapeutics
The Week’s Biggest Funding Rounds: Another Billion-Dollar AI Raise Leads List That Includes Lots Of Biotech And More AI
news • May 30, 2025
GRIN Therapeutics and Angelini Pharma Enter into Exclusive Collaboration to Develop and Commercialize Radiprodil Outside North America
webwire • May 29, 2025
GRIN raises $140 million and enters global pact for epilepsy candidate
thepharmaletter • May 29, 2025
Grin Therapeutics Closes $140M Series D Financing
finsmes • May 29, 2025
GRIN Therapeutics and Angelini Pharma Enter into Exclusive Collaboration to Develop and Commercialize Radiprodil Outside North America
vcaonline • May 29, 2025
GRIN Therapeutics Management
Leadership team at GRIN Therapeutics
CEO & President
Bruce Leuchter
CMO
Michael Panzara
Join now and verify your accreditation status to gain access to:
- GRIN Therapeutics Current Valuation
- GRIN Therapeutics Stock Price
- GRIN Therapeutics Management
- Available deals in GRIN Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- GRIN Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- GRIN Therapeutics Revenue and Financials
- GRIN Therapeutics Highlights
- GRIN Therapeutics Business Model
- GRIN Therapeutics Risk Factors
- GRIN Therapeutics Research Report from SACRA Research
Trading GRIN Therapeutics Stock
How to invest in GRIN Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like GRIN Therapeutics through EquityZen funds. These investments are made available by existing GRIN Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell GRIN Therapeutics stock?
Shareholders can sell their GRIN Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 370K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."